AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23519233 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training Athletes (RTA)
Number of subjects: 22
Study 21745121 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 6689
Study 21745121 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 6689
Study 19101420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg)
Number of subjects: 68
Study 19101420 — intervention group
Group type: COMPARATOR
Intervention: Control group (phacoemulsification with intraocular lens implantation alone)
Number of subjects: 68
Study 16441730 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing bioactive glass (NovaMin)
Number of subjects: 100
Study 16441730 — intervention group
Group type: COMPARATOR
Intervention: Placebo control dentifrice
Number of subjects: 100
Study 15210260 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseled group
Number of subjects: 90
Study 15210260 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 90
Study 11083260 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with DMARDs (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Number of subjects: 195
Study 11083260 — intervention group
Group type: COMPARATOR
Intervention: Single DMARD therapy with or without prednisolone
Number of subjects: 195
Study 11083260 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with DMARDs
Number of subjects: 195
Study 9122365 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg thiamine daily for 2 months
Number of subjects: 120
Study 9122365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8452112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron radiation (mixed-beam treatment schedule)
Number of subjects: 91
Study 8452112 — intervention group
Group type: COMPARATOR
Intervention: Conventional photon radiation
Number of subjects: 91
Study 3780991 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 158
Study 3780991 — intervention group
Group type: COMPARATOR
Intervention: Polypectomy or local excision
Number of subjects: 158
Study 31873776 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) technique
Number of subjects: 50
Study 31873776 — intervention group
Group type: COMPARATOR
Intervention: Shaker exercises
Number of subjects: 50
Study 30096702 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin (SP): S‐1 40 mg/m2 for 21 days plus cisplatin 60 mg/m2 (q5w)
Number of subjects: 110
Study 30096702 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus cisplatin (XP): capecitabine 1000 mg/m2 for 14 days plus cisplatin 80 mg/m2 (q3w)
Number of subjects: 110
Study 28946892 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperPath approach
Number of subjects: 92
Study 28946892 — intervention group
Group type: COMPARATOR
Intervention: Conventional posterior approach
Number of subjects: 92
Study 25730028 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT plus DC-CIK immunotherapy (study group, N = 34)
Number of subjects: 68
Study 25730028 — intervention group
Group type: COMPARATOR
Intervention: IMRT only (control group, N = 34)
Number of subjects: 68
Study 25730028 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT plus DC-CIK immunotherapy (study group)
Number of subjects: 68
Study 25730028 — intervention group
Group type: COMPARATOR
Intervention: IMRT only (control group)
Number of subjects: 68
Study 23452966 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of the maxillary first premolars (group 1, n=25)
Number of subjects: 50
Study 23452966 — intervention group
Group type: COMPARATOR
Intervention: No extractions (group 2, n=25)
Number of subjects: 50
Study 21594659 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 µg clonidine
Number of subjects: 40
Study 21594659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18833168 — intervention group
Group type: EXPERIMENTAL
Intervention: Proflusak (fluoxetine)
Number of subjects: 68
Study 18833168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 16497649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 90
Study 16497649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime-axetil
Number of subjects: 90
Study 16497649 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 16497649 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral AOM
Number of subjects: 90
Study 16497649 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral AOM
Number of subjects: 90
Study 14959468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipin‐retard (40 mg/day, 20 mg twice a day)
Number of subjects: 20
Study 14959468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipin‐retard (20 mg/day) in combination with metoprolol (100 mg/day, 50 mg twice a day)
Number of subjects: 20
Study 15562712 — intervention group
Group type: EXPERIMENTAL
Intervention: Dan Shao Tang (DST) and western medicine
Number of subjects: 60
Study 15562712 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60
Study 9876189 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-6 month group
Number of subjects: 96
Study 9876189 — intervention group
Group type: COMPARATOR
Intervention: 0-12 month group
Number of subjects: 96
Study 8025366 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced amino acid solution (2510 kJ/24 h) for 6 h
Number of subjects: 26
Study 8025366 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-enriched solution (2510 kJ/24 h) for 6 h
Number of subjects: 26
Study 8025366 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric glucose
Number of subjects: 26
Study 8025366 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced amino acid solution (2510 kJ/24 h) for 6 h in healthy volunteers
Number of subjects: 26
Study 8025366 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-enriched solution (2510 kJ/24 h) for 6 h in healthy volunteers
Number of subjects: 26
Study 2605386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mm vented mould
Number of subjects: 106
Study 2605386 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mm vented mould
Number of subjects: 106
Study 2605386 — intervention group
Group type: COMPARATOR
Intervention: Unvented mould
Number of subjects: 106
Study 31150574 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus ADT
Number of subjects: 1052
Study 31150574 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 1052
Study 28632545 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMISS-TLIF
Number of subjects: 61
Study 28632545 — intervention group
Group type: COMPARATOR
Intervention: Open TLIF
Number of subjects: 61
Study 25391616 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-focused genetic testing (TFGT)
Number of subjects: 36
Study 25391616 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-genetic health professionals' preference for information delivery
Number of subjects: 36
Study 25391616 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to implementation of TFGT
Number of subjects: 36
Study 25391616 — intervention group
Group type: EXPERIMENTAL
Intervention: Future of TFGT in clinical care
Number of subjects: 36
Study 24103725 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wristbands
Number of subjects: 26
Study 24103725 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure wristbands
Number of subjects: 26
Study 21362184 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participants (invited from population registers)
Number of subjects: 202638
Study 21362184 — intervention group
Group type: COMPARATOR
Intervention: Invited population (not participating)
Number of subjects: 202638
Study 19499960 — intervention group
Group type: COMPARATOR
Intervention: olmesartan/placebo
Number of subjects: 538
Study 19499960 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan/amlodipine 20 mg/5 mg
Number of subjects: 538
Study 19499960 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan/amlodipine 20 mg/10 mg
Number of subjects: 538
Study 17898352 — intervention group
Group type: COMPARATOR
Intervention: Glycine
Number of subjects: 157
Study 17898352 — intervention group
Group type: COMPARATOR
Intervention: D-cycloserine
Number of subjects: 157
Study 17898352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 15485012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg once daily
Number of subjects: 594
Study 15485012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily
Number of subjects: 594
Study 15485012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study 11535993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (250 microg/m(2))
Number of subjects: 11
Study 11535993 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (250 microg/m(2))
Number of subjects: 11
Study 9506856 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg T4 daily for two months (Group C)
Number of subjects: 110
Study 9506856 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg T4 daily for two months (Group D)
Number of subjects: 110
Study 9506856 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg T4 daily for two months (Group A)
Number of subjects: 110
Study 9506856 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg T4 daily for two months (Group B)
Number of subjects: 110
Study 9506856 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine administration in group D (ThAab negative)
Number of subjects: 110
Study 8090162 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 359
Study 8090162 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 359
Study 31968068 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital CBT-I
Number of subjects: 208
Study 31968068 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 208
Study 29777975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (BEV)
Number of subjects: 102
Study 29777975 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (CT)
Number of subjects: 102
Study 27469414 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroAiD
Number of subjects: 0
Study 27469414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24895144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (100 mg bid)
Number of subjects: 3
Study 21562819 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine (250 mg/kg bm)
Number of subjects: 27
Study 21562819 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 27
Study 21562819 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 20617176 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 282
Study 20617176 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 282
Study 20617176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal infections (other than pneumocystis)
Number of subjects: 282
Study 20617176 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD4+ T-cell counts
Number of subjects: 282
Study 20617176 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment CD4+ T-cell counts
Number of subjects: 282
Study 20617176 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HIV RNA levels
Number of subjects: 282
Study 20617176 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment HIV RNA levels
Number of subjects: 282
Study 20617176 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids during OI management
Number of subjects: 282
Study 20617176 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of ART
Number of subjects: 282
Study 18479895 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 400microg
Number of subjects: 635
Study 18479895 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 200microg
Number of subjects: 635
Study 18479895 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 50microg
Number of subjects: 635
Study 18479895 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 100microg
Number of subjects: 635
Study 18479895 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18microg
Number of subjects: 635
Study 18479895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study 15735210 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular supervised physical exercise training
Number of subjects: 297
Study 15735210 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 297
Study 12540386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules (4 g/d, consisting of 45% eicosapentaenoic acid and 39% docosahexaenoic acid as ethyl esters)
Number of subjects: 24
Study 12540386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules (4 g/d)
Number of subjects: 24
Study 12540386 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil, 4 g/d)
Number of subjects: 24
Study 11052029 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid barrier
Number of subjects: 148
Study 11052029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhydrocolloid barrier
Number of subjects: 148
Study 11052029 — intervention group
Group type: COMPARATOR
Intervention: Control group (taped directly to skin)
Number of subjects: 148
Study 8829930 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA 5%
Number of subjects: 100
Study 8829930 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA 5% plus glyceryl trinitrate
Number of subjects: 100
Study 8829930 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 100
Study 1856147 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin given once daily (od)
Number of subjects: 0
Study 1856147 — intervention group
Group type: COMPARATOR
Intervention: Amikacin given twice daily (bd)
Number of subjects: 0
Study 6614032 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive feedback
Number of subjects: 64
Study 6614032 — intervention group
Group type: COMPARATOR
Intervention: videotape control
Number of subjects: 64
Study 6614032 — intervention group
Group type: COMPARATOR
Intervention: questionnaire feedback
Number of subjects: 64
Study 6614032 — intervention group
Group type: COMPARATOR
Intervention: questionnaire control
Number of subjects: 64
Study 30339721 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Triple P
Number of subjects: 112
Study 30339721 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 112
Study 30339721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Baby Triple P and Care as usual)
Number of subjects: 112
Study 26341303 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline thrombocytopenia (TP)
Number of subjects: 10603
Study 24481679 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (single-agent)
Number of subjects: 84
Study 22718083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal telecardiology service
Number of subjects: 67
Study 20493663 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 56
Study 20493663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 56
Study 20493663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 56
Study 18317369 — intervention group
Group type: COMPARATOR
Intervention: NF + CAFF
Number of subjects: 7
Study 18317369 — intervention group
Group type: EXPERIMENTAL
Intervention: WAT + CAFF
Number of subjects: 7
Study 18317369 — intervention group
Group type: EXPERIMENTAL
Intervention: CES + CAFF
Number of subjects: 7
Study 18317369 — intervention group
Group type: COMPARATOR
Intervention: NF
Number of subjects: 7
Study 18317369 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (6 mg.kg body weight)
Number of subjects: 7
Study 18317369 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 7
Study 16043426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine tartrate
Number of subjects: 20
Study 16043426 — intervention group
Group type: COMPARATOR
Intervention: Internal standard: Oxybutynin
Number of subjects: 20
Study 11788381 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Carnitine L-tartrate (2 g L-carnitine/day)
Number of subjects: 10
Study 11788381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10027480 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem retard (D)
Number of subjects: 256
Study 10027480 — intervention group
Group type: COMPARATOR
Intervention: atenolol (A)
Number of subjects: 256
Study 8835550 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with auranofin within one year of diagnosis of RA.
Number of subjects: 137
Study 8835550 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment with slow acting antirheumatic drugs (SAARD) after 8 months compared to the early treatment group.
Number of subjects: 137
Study 2144236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training intervention
Number of subjects: 30
Study 2144236 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 30
Study 7280753 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg) administered intramuscularly before repeat BTM and gamma camera studies
Number of subjects: 21
Study 7280753 — intervention group
Group type: COMPARATOR
Intervention: Normal saline administered before gamma camera studies
Number of subjects: 21
Study 31649396 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 336
Study 31649396 — intervention group
Group type: EXPERIMENTAL
Intervention: Huff's manoeuvre
Number of subjects: 336
Study 31649396 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 336
Study 31649396 — intervention group
Group type: EXPERIMENTAL
Intervention: FIC presence
Number of subjects: 336
Study 29542208 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, left DLPFC, 20 sessions over 4 weeks)
Number of subjects: 26
Study 29542208 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 26
Study 27643343 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM) for 8 weeks
Number of subjects: 180
Study 27643343 — intervention group
Group type: COMPARATOR
Intervention: Office Blood Pressure Management
Number of subjects: 180
Study 27643343 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM)
Number of subjects: 180
Study 25187749 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringoplasty alone
Number of subjects: 40
Study 25187749 — intervention group
Group type: COMPARATOR
Intervention: Myringoplasty with cortical mastoidectomy
Number of subjects: 40
Study 21804414 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (NPWT) applied to closed surgical incisions (Group B)
Number of subjects: 249
Study 21804414 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative dressings (Group A)
Number of subjects: 249
Study 19920818 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus CVP (R-CVP)
Number of subjects: 0
Study 19920818 — intervention group
Group type: COMPARATOR
Intervention: CVP alone
Number of subjects: 0
Study 18616675 — intervention group
Group type: EXPERIMENTAL
Intervention: Calvados (13% ethanol)
Number of subjects: 19
Study 18616675 — intervention group
Group type: EXPERIMENTAL
Intervention: Shochu (13% ethanol)
Number of subjects: 19
Study 18616675 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (13% ethanol)
Number of subjects: 19
Study 18616675 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer (5% ethanol)
Number of subjects: 19
Study 18616675 — intervention group
Group type: EXPERIMENTAL
Intervention: ALDH2 homozygotes
Number of subjects: 19
Study 18616675 — intervention group
Group type: EXPERIMENTAL
Intervention: ALDH2 heterozygotes
Number of subjects: 19
Study 16395995 — intervention group
Group type: EXPERIMENTAL
Intervention: StatXact software for exact tests incorporating new methods for non-inferiority and confidence intervals
Number of subjects: 0
Study 16395995 — intervention group
Group type: EXPERIMENTAL
Intervention: Berger and Boos confidence interval method for testing equality of two proportions
Number of subjects: 0
Study 14571615 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhifeng Huatan Pingxiao recipe (ZHPR)
Number of subjects: 60
Study 14571615 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60
Study 10918719 — intervention group
Group type: COMPARATOR
Intervention: Parasympathetic function assessment (E:I ratio)
Number of subjects: 35
Study 10918719 — intervention group
Group type: COMPARATOR
Intervention: Parasympathetic function assessment (Valsalva ratio)
Number of subjects: 35
Study 10918719 — intervention group
Group type: COMPARATOR
Intervention: Parasympathetic function assessment (30:15 ratio)
Number of subjects: 35
Study 10918719 — intervention group
Group type: COMPARATOR
Intervention: Diastolic blood pressure response to head-up tilt
Number of subjects: 35
Study 10918719 — intervention group
Group type: COMPARATOR
Intervention: Heart rate response to head-up tilt
Number of subjects: 35
Study 10918719 — intervention group
Group type: COMPARATOR
Intervention: Anxiety score
Number of subjects: 35
Study 8812822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (CATCH program)
Number of subjects: 6000
Study 8812822 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6000
Study 1550035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meals containing 0, 33, 67, 100, and 134 kJ/kg fat‐free mass (0, 8, 16, 24, and 32 kcal/kg)
Number of subjects: 0
Study 1550035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meals
Number of subjects: 0
Study 3699692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydration (total restriction of water intake)
Number of subjects: 36
Study 3699692 — intervention group
Group type: COMPARATOR
Intervention: Euhydration (water intake of 20 ml/kg body weight)
Number of subjects: 36